Franklin Resources Inc. reduced its position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 48.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,291 shares of the medical instruments supplier's stock after selling 3,153 shares during the period. Franklin Resources Inc. owned about 0.06% of Mesa Laboratories worth $434,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Conestoga Capital Advisors LLC lifted its holdings in shares of Mesa Laboratories by 8.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 573,037 shares of the medical instruments supplier's stock valued at $75,566,000 after purchasing an additional 43,927 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Mesa Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 382,856 shares of the medical instruments supplier's stock valued at $50,487,000 after acquiring an additional 5,274 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Mesa Laboratories in the fourth quarter worth approximately $32,677,000. State Street Corp raised its holdings in shares of Mesa Laboratories by 9.2% during the third quarter. State Street Corp now owns 214,148 shares of the medical instruments supplier's stock valued at $27,809,000 after purchasing an additional 18,128 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Mesa Laboratories by 4.8% during the third quarter. Geode Capital Management LLC now owns 124,761 shares of the medical instruments supplier's stock valued at $16,205,000 after purchasing an additional 5,771 shares during the period. 90.60% of the stock is owned by institutional investors.
Insider Activity at Mesa Laboratories
In other news, CEO Gary M. Owens sold 21,000 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares in the company, valued at $5,369,887.67. This represents a 32.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 4.40% of the stock is currently owned by company insiders.
Mesa Laboratories Trading Down 0.8 %
NASDAQ:MLAB opened at $112.01 on Friday. The company has a 50 day simple moving average of $128.51 and a two-hundred day simple moving average of $127.92. The company has a market cap of $608.66 million, a PE ratio of -2.42 and a beta of 0.92. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. Mesa Laboratories, Inc. has a 12 month low of $83.68 and a 12 month high of $155.12.
Mesa Laboratories (NASDAQ:MLAB - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 EPS for the quarter, topping the consensus estimate of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. Research analysts forecast that Mesa Laboratories, Inc. will post 8 earnings per share for the current year.
Mesa Laboratories Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.57%. The ex-dividend date of this dividend is Friday, May 30th. Mesa Laboratories's payout ratio is -1.38%.
Mesa Laboratories Company Profile
(
Free Report)
Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.
See Also
Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesa Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.
While Mesa Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
